270 related articles for article (PubMed ID: 26088126)
1. Academic drug discovery: current status and prospects.
Everett JR
Expert Opin Drug Discov; 2015; 10(9):937-44. PubMed ID: 26088126
[TBL] [Abstract][Full Text] [Related]
2. Drug discovery: new models for industry-academic partnerships.
Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
[TBL] [Abstract][Full Text] [Related]
3. The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development.
Takebe T; Imai R; Ono S
Clin Transl Sci; 2018 Nov; 11(6):597-606. PubMed ID: 29940695
[TBL] [Abstract][Full Text] [Related]
4. The Drug Discovery Portal: a resource to enhance drug discovery from academia.
Clark RL; Johnston BF; Mackay SP; Breslin CJ; Robertson MN; Harvey AL
Drug Discov Today; 2010 Aug; 15(15-16):679-83. PubMed ID: 20547242
[TBL] [Abstract][Full Text] [Related]
5. Are academic drug discovery efforts receiving more recognition with declining industry efficiency?
Bryans JS; Kettleborough CA; Solari R
Expert Opin Drug Discov; 2019 Jul; 14(7):605-607. PubMed ID: 30907161
[No Abstract] [Full Text] [Related]
6. Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry.
Litten RZ; Ryan M; Falk D; Fertig J
Alcohol Clin Exp Res; 2014 May; 38(5):1196-9. PubMed ID: 24689461
[TBL] [Abstract][Full Text] [Related]
7. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models.
Chung TD
Comb Chem High Throughput Screen; 2014 Mar; 17(3):272-89. PubMed ID: 24409951
[TBL] [Abstract][Full Text] [Related]
8. Accessing external innovation in drug discovery and development.
Tufféry P
Expert Opin Drug Discov; 2015 Jun; 10(6):579-89. PubMed ID: 25910932
[TBL] [Abstract][Full Text] [Related]
9. Drug discovery through industry-academic partnerships.
Gray NS
Nat Chem Biol; 2006 Dec; 2(12):649-53. PubMed ID: 17108976
[No Abstract] [Full Text] [Related]
10. Non-stoichiometric inhibition in integrated lead finding - a literature review.
Klumpp M
Expert Opin Drug Discov; 2016; 11(2):149-62. PubMed ID: 26653534
[TBL] [Abstract][Full Text] [Related]
11. How academic labs can approach the drug discovery process as a way to synergize with big pharma.
Loregian A; Palù G
Trends Microbiol; 2013 Jun; 21(6):261-4. PubMed ID: 23731493
[TBL] [Abstract][Full Text] [Related]
12. Bringing together the academic drug discovery community.
Slusher BS; Conn PJ; Frye S; Glicksman M; Arkin M
Nat Rev Drug Discov; 2013 Nov; 12(11):811-2. PubMed ID: 24172316
[TBL] [Abstract][Full Text] [Related]
13. From HTS to Phase I: the Institute for Therapeutics Discovery and Development at the University of Minnesota.
Dosa PI; Georg GI; Gurvich VJ; Hawkinson JE; Walters MA; Wong HL
Comb Chem High Throughput Screen; 2014 Mar; 17(3):231-40. PubMed ID: 24409956
[TBL] [Abstract][Full Text] [Related]
14. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
15. The role of HTS in drug discovery at the University of Michigan.
Larsen MJ; Larsen SD; Fribley A; Grembecka J; Homan K; Mapp A; Haak A; Nikolovska-Coleska Z; Stuckey JA; Sun D; Sherman DH
Comb Chem High Throughput Screen; 2014 Mar; 17(3):210-30. PubMed ID: 24409957
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical pipeline.
Lowen T
Minn Med; 2011 Oct; 94(10):16-8. PubMed ID: 23256279
[No Abstract] [Full Text] [Related]
17. Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays.
Gul S; Hadian K
Expert Opin Drug Discov; 2014 Dec; 9(12):1393-404. PubMed ID: 25374163
[TBL] [Abstract][Full Text] [Related]
18. Pursuit of personalized anticancer therapy: leveraging collaboration between academia and the biotech/pharmaceutical industry.
Buck E; Mulvihill M; Iwata KK
Mt Sinai J Med; 2010; 77(4):358-65. PubMed ID: 20687181
[TBL] [Abstract][Full Text] [Related]
19. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
Thomas CE; Will Y
Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
